MA51154A - Variants de cd19 - Google Patents
Variants de cd19Info
- Publication number
- MA51154A MA51154A MA051154A MA51154A MA51154A MA 51154 A MA51154 A MA 51154A MA 051154 A MA051154 A MA 051154A MA 51154 A MA51154 A MA 51154A MA 51154 A MA51154 A MA 51154A
- Authority
- MA
- Morocco
- Prior art keywords
- variants
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4203—Receptors for growth factors
- A61K40/4204—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4203—Receptors for growth factors
- A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762599211P | 2017-12-15 | 2017-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51154A true MA51154A (fr) | 2020-10-21 |
Family
ID=66819735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051154A MA51154A (fr) | 2017-12-15 | 2018-12-14 | Variants de cd19 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11891426B2 (fr) |
| EP (1) | EP3723788A4 (fr) |
| JP (1) | JP2021508443A (fr) |
| KR (1) | KR102847676B1 (fr) |
| CN (1) | CN111936158A (fr) |
| AU (1) | AU2018385756B2 (fr) |
| CA (1) | CA3085781A1 (fr) |
| IL (1) | IL275335A (fr) |
| MA (1) | MA51154A (fr) |
| MX (1) | MX2020006297A (fr) |
| WO (1) | WO2019118918A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111163803B (zh) | 2017-08-11 | 2025-05-09 | 希望之城公司 | 表达car t细胞靶物的溶瘤病毒及其用途 |
| WO2019118918A1 (fr) | 2017-12-15 | 2019-06-20 | Aleta Biotherapeutics Inc. | Variants de cd19 |
| WO2020113063A1 (fr) * | 2018-11-30 | 2020-06-04 | Aleta Biotherapeutics Inc. | Anticorps à domaine unique ciblant cll-1 |
| US12590135B2 (en) * | 2019-03-01 | 2026-03-31 | Universität Für Bodenkultur Wien | Stabilized extracellular domain of CD19 |
| WO2020219989A1 (fr) * | 2019-04-26 | 2020-10-29 | Aleta Biotherapeutics Inc. | Compositions et procédés de traitement du cancer |
| JP7796414B2 (ja) * | 2019-10-17 | 2026-01-09 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | Clec12a抗体断片配列及び方法 |
| US20210340524A1 (en) * | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
| US20240024475A1 (en) * | 2020-12-01 | 2024-01-25 | Cure Genetics Co., Ltd | Antigen-Binding Protein Targeting CD70 and Use Thereof |
| CN114181319A (zh) * | 2021-11-26 | 2022-03-15 | 北京双赢科创生物科技有限公司 | 用于靶向肿瘤细胞的多肽偶联物及其制备方法与应用 |
| CN115109159B (zh) * | 2022-06-24 | 2025-03-04 | 海珂分子(北京)科技有限责任公司 | Cd19突变蛋白及其应用 |
| WO2024020596A1 (fr) * | 2022-07-22 | 2024-01-25 | Villanova University | Procédés et compositions comprenant des protéines de fusion pour l'identification de cellules pour l'immunothérapie |
| US12698512B2 (en) | 2023-11-06 | 2026-08-04 | City Of Hope | Methods comprising oncolytic viruses expressing CD19T and bispecific T cell engagers |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2079802C (fr) | 1990-04-05 | 2001-09-18 | Roberto Crea | Mutagenese dirigee |
| JPH07503124A (ja) | 1991-06-14 | 1995-04-06 | ゾーマ・コーポレーション | 微生物によって生産される抗体断片とそれらの複合体 |
| US5866344A (en) | 1991-11-15 | 1999-02-02 | Board Of Regents, The University Of Texas System | Antibody selection methods using cell surface expressed libraries |
| US20030036092A1 (en) | 1991-11-15 | 2003-02-20 | Board Of Regents, The University Of Texas System | Directed evolution of enzymes and antibodies |
| US6300065B1 (en) | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
| JP3876002B2 (ja) | 1997-04-14 | 2007-01-31 | ミクロメート・アクチエンゲゼルシャフト | 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用 |
| US20050136428A1 (en) | 2003-06-27 | 2005-06-23 | Roberto Crea | Look-through mutagenesis |
| EP2009990B1 (fr) | 2006-04-07 | 2016-09-21 | The Board of Regents of The University of Texas System | Procedes et compositions portant sur des particules de phage de virus adenoassocie |
| RS53263B (sr) * | 2006-08-14 | 2014-08-29 | Xencor Inc. | Optimizovana antitela usmerena na cd19 |
| WO2008140961A2 (fr) | 2007-05-08 | 2008-11-20 | The Government Of The U.S.A, As Represented By The Secretary, Department Of Health And Human Services | Pseudovirus de papillomavirus pour détection et thérapie de tumeurs |
| EP3543256A1 (fr) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Compositions d anticorps modifiées et leurs procédés de production et d'utilisation |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| PE20150605A1 (es) | 2012-04-27 | 2015-05-28 | Cytomx Therapeutics Inc | Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico |
| RS62471B1 (sr) * | 2014-04-16 | 2021-11-30 | Juno Therapeutics Gmbh | Metode, kompleti i uređaji za proširenje populacije ćelija |
| JP2018528191A (ja) | 2015-08-19 | 2018-09-27 | ラトガーズ, ザ ステイト ユニバーシティ オブ ニュー ジャージー | 抗体を生成する新規な方法 |
| EP3356405B1 (fr) | 2015-10-02 | 2026-07-08 | F. Hoffmann-La Roche AG | Anticorps anti-humain cd19 à affinité élevée |
| WO2017075537A1 (fr) | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions et méthodes pour le du traitement du cancer |
| MA43134A (fr) * | 2015-10-30 | 2018-09-05 | Aleta Biotherapeutics Inc | Compositions et méthodes de transduction tumorale |
| EP3585817A4 (fr) * | 2017-02-22 | 2020-12-02 | Aleta Biotherapeutics Inc. | Compositions et procédés de traitement du cancer |
| AU2018227583B2 (en) * | 2017-03-03 | 2023-06-01 | Obsidian Therapeutics, Inc. | CD19 compositions and methods for immunotherapy |
| WO2019118918A1 (fr) | 2017-12-15 | 2019-06-20 | Aleta Biotherapeutics Inc. | Variants de cd19 |
-
2018
- 2018-12-14 WO PCT/US2018/065835 patent/WO2019118918A1/fr not_active Ceased
- 2018-12-14 MX MX2020006297A patent/MX2020006297A/es unknown
- 2018-12-14 KR KR1020207020341A patent/KR102847676B1/ko active Active
- 2018-12-14 MA MA051154A patent/MA51154A/fr unknown
- 2018-12-14 JP JP2020532683A patent/JP2021508443A/ja active Pending
- 2018-12-14 EP EP18887913.4A patent/EP3723788A4/fr active Pending
- 2018-12-14 US US16/954,002 patent/US11891426B2/en active Active
- 2018-12-14 CA CA3085781A patent/CA3085781A1/fr active Pending
- 2018-12-14 CN CN201880088889.XA patent/CN111936158A/zh active Pending
- 2018-12-14 AU AU2018385756A patent/AU2018385756B2/en active Active
-
2020
- 2020-06-14 IL IL275335A patent/IL275335A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL275335A (en) | 2020-07-30 |
| MX2020006297A (es) | 2020-12-07 |
| KR102847676B1 (ko) | 2025-08-21 |
| JP2021508443A (ja) | 2021-03-11 |
| US20210079060A1 (en) | 2021-03-18 |
| EP3723788A1 (fr) | 2020-10-21 |
| AU2018385756A1 (en) | 2020-07-09 |
| KR20200117997A (ko) | 2020-10-14 |
| CA3085781A1 (fr) | 2019-06-20 |
| US11891426B2 (en) | 2024-02-06 |
| CN111936158A (zh) | 2020-11-13 |
| AU2018385756B2 (en) | 2025-10-09 |
| WO2019118918A1 (fr) | 2019-06-20 |
| EP3723788A4 (fr) | 2022-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3731771T3 (da) | V462033dk00 | |
| EP3723788A4 (fr) | Variants de cd19 | |
| CL2018000524S1 (es) | Golilla | |
| EP3589248A4 (fr) | Cryothérapies | |
| DE202018003363U8 (de) | Handgelenkssphygmomanometer | |
| EP3634404C0 (fr) | Inhibiteurs de magl à base de pyrazole | |
| EP3697802A4 (fr) | Analogues de saponine triterpénique | |
| EP3588580A4 (fr) | Diode schottky mos à tranchée | |
| DK3351526T3 (da) | Diisopentylterephthalat | |
| PT4039675T (pt) | Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenilo | |
| EP3634397A4 (fr) | Chromophores ir à base de polyméthine hétérocyclyle | |
| EP3619321A4 (fr) | Variants de polymérase de type dp04 | |
| EP3654852A4 (fr) | Garrot | |
| DK3568655T3 (da) | Rekuperator | |
| DK3571580T3 (da) | Load-logical-and-shift-guarded-instruktion | |
| DK3612237T3 (da) | Genterapi | |
| EP3611402A4 (fr) | Servocylindre | |
| EP3615471A4 (fr) | Immunocapteur plasmo-photoélectronique | |
| EP3684343A4 (fr) | Superparticules améliorées | |
| EP3669219C0 (fr) | Réseau echelle | |
| EP3714787A4 (fr) | Biocapteur | |
| IT201700065996A1 (it) | Transpallet | |
| PL3755363T3 (pl) | Warianty plantarycyny nc8alfabeta | |
| DK3576686T3 (da) | Brokbind | |
| DK3568506T3 (da) | Offeranode |